Active, not recruitingPhase 3NCT03861273
A Study to Evaluate the Efficacy and Safety of Factor IX Gene Therapy With PF-06838435 in Adult Males With Moderately Severe to Severe Hemophilia B
Studying Hemophilia
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Pfizer
- Principal Investigator
- Pfizer CT.gov Call CenterPfizer
- Intervention
- PF-06838435/ fidanacogene elaparvovec(biological)
- Enrollment
- 51 enrolled
- Eligibility
- 18-65 years · MALE
- Timeline
- 2019 – 2031
Study locations (30)
- UCSF IDS Pharmacy, San Francisco, California, United States
- University of California, San Francisco - Clinical Research Center, San Francisco, California, United States
- University of California, San Francisco - Outpatient Hematology Clinic, San Francisco, California, United States
- The Regents of the University of California, San Francisco campus, San Francisco, California, United States
- Hemophilia and Thrombosis Center at the University of Colorado Anschutz Medical Campus, Aurora, Colorado, United States
- Regents of the University of Colorado University of Colorado Denver, Office of Grants and Contracts, Aurora, Colorado, United States
- Indiana Hemophilia & Thrombosis Center, Inc., Indianapolis, Indiana, United States
- Indiana Hemophilia and Thrombosis Center, Inc, Indianapolis, Indiana, United States
- Innovative Hematology, Inc., Indianapolis, Indiana, United States
- St. Vincent Hospital & Health Care Center, Inc., Indianapolis, Indiana, United States
- Madison Radiological Group, Madison, Mississippi, United States
- Mississippi Center for Advanced Medicine, Madison, Mississippi, United States
- Center for Human Phenomic Science, Philadelphia, Pennsylvania, United States
- Investigational Drug Service, Philadelphia, Pennsylvania, United States
- Penn Blood Disorder Center, Philadelphia, Pennsylvania, United States
- +15 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT03861273 on ClinicalTrials.govOther trials for Hemophilia
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE4NCT07406139PCC Treatment for Hemophilia Patients With Inhibitor（2022PCC-A）Institute of Hematology & Blood Diseases Hospital, China
- RECRUITINGPHASE3NCT04563520SAFE Study: Safety of aPCC Following Emicizumab ProphylaxisEmory University
- RECRUITINGNCT07101926Monitoring of Anti-TFPI in HemophiliaHospices Civils de Lyon
- RECRUITINGPHASE4NCT06941870Efanesoctocog Alfa Prophylaxis in Patients With Hemophilia A With Synovial HypertrophySanofi
- RECRUITINGNCT07314983Long-term Anticoagulation in a Patient With Severe Hemophilia AUniversity Hospital, Strasbourg, France
- RECRUITINGPHASE4NCT06940830Long-term Study Evaluating Joint Health in People With Haemophilia A Receiving Real-world Prophylactic Treatment With Efanesoctocog AlfaSwedish Orphan Biovitrum
- RECRUITINGPHASE1NCT06703606A Study to Learn About How Changing Therapy From Emicizumab to Marstacimab Affects People With the Severe Hemophilia A.Pfizer
- RECRUITINGPHASE3NCT06833983To Evaluate the Clinical Study of GS1191-0445 Injection in the Treatment of Hemophilia AGritgen Therapeutics Co., Ltd.